413 related articles for article (PubMed ID: 7549063)
1. Mechanisms of physiological fibrinolysis.
Lijnen HR; Collen D
Baillieres Clin Haematol; 1995 Jun; 8(2):277-90. PubMed ID: 7549063
[TBL] [Abstract][Full Text] [Related]
2. Elements of the fibrinolytic system.
Lijnen HR
Ann N Y Acad Sci; 2001; 936():226-36. PubMed ID: 11460480
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein (a) regulates plasmin generation and inhibition.
Edelberg J; Pizzo SV
Chem Phys Lipids; 1994 Jan; 67-68():363-8. PubMed ID: 8187236
[TBL] [Abstract][Full Text] [Related]
5. The Role of Fibrinolytic System in Health and Disease.
Kwaan HC
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563651
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
7. The fibrinolytic system in man.
Collen D; Lijnen HR
Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
[TBL] [Abstract][Full Text] [Related]
8. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
9. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
10. Fibrin-specific thrombolytic agents.
Collen D
Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow.
McWilliam N; Robbie L; Booth N; Bennett B
Br J Haematol; 1998 Jun; 101(4):626-31. PubMed ID: 9674732
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
14. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
Sugiyama N; Iwamoto M; Abiko Y
Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.
Haj MA; Robbie LA; Croll A; Adey GD; Bennett B
Intensive Care Med; 1998 Mar; 24(3):258-61. PubMed ID: 9565810
[TBL] [Abstract][Full Text] [Related]
16. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
17. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
19. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
Silva MM; Thelwell C; Williams SC; Longstaff C
J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
[TBL] [Abstract][Full Text] [Related]
20. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
